- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Fresenius Kabi Debuts New Generic MRI Contrast Agent
The indications for Gadobutrol injection, a generic substitute for Gadavist, include neurovascular and cardiovascular assessments as well as breast malignancy detection with magnetic resonance imaging (MRI).
Fresenius Kabi has launched Gadobutrol Injection, a generic contrast alternative to Gadavist, for use in magnetic resonance imaging (MRI).
A high relaxivity macrocyclic agent, Gadobutrol Injection offers a range of MRI indications including:
• detection and assessment of malignant breast disease in adults;
• diagnosis and evaluation of supra-aortic or renal artery disease in adults and pediatric patients, including term neonates;
• detection of a disrupted blood brain barrier and/or abnormal vascularity in patients of all ages, including term neonates; and
• assessment of myocardial perfusion and late gadolinium enhancement in patients with suspected or known coronary artery disease (CAD).
“Fresenius Kabi is pleased to introduce Gadobutrol Injection as the newest addition to our (United States) radiology portfolio, expanding the range of cost-effective contrast agent options available to hospitals and clinics,” noted John Ducker, the president and CEO of Fresenius Kabi USA.
The company said Gadobutrol Injection is available in single dose vials at 2, 7.5, 10 and 15 mL
(Editor’s note: For related content, see “MRI Study: Half-Dose Gadopiclenol Offers Similar Visualization and Safety as Full-Dose Gadobutrol.”)
